CD34+ Cell Therapy for No-Option Refractory Disabling Angina: Time for FDA Approval?

Cardiovasc Revasc Med

Cedars Sinai Medical Center, Los Angeles, CA, United States of America; Minneapolis Heart Institute Foundation, Minneapolis, MN, United States of America; The Lindner Center for Research and Education, The Christ Hospital, Cincinnati, OH, United States of America. Electronic address:

Published: March 2019

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.carrev.2019.01.012DOI Listing

Publication Analysis

Top Keywords

cd34+ cell
4
cell therapy
4
therapy no-option
4
no-option refractory
4
refractory disabling
4
disabling angina
4
angina time
4
time fda
4
fda approval?
4
cd34+
1

Similar Publications

The Innate Lymphoid Cells (ILCs) are a family of innate immune cells composed by the Natural Killer (NK) cells and the helper ILCs (hILCs) (ILC1, ILC2, ILC3), both developing from a common ILC precursor (ILCP) derived from hematopoietic stem cells (HSCs). A correct ILC reconstitution is crucial, particularly in patients receiving HSC transplantation (HSCT), the only therapeutic option for many adult and pediatric high-risk hematological malignancies. Indeed, mainly thanks to their cytotoxic activity, NK cells have a strong Graft-versus-Leukemia (GvL) effect.

View Article and Find Full Text PDF

Introduction And Importance: Retiform hemangioendothelioma(RH) is a rare vascular tumor affecting patients over a wide age range without a gender predilection; only about 50 cases have been described so far.

Case Presentation: We report a case of submandibular retiform hemangioendothelioma in a 58-year-old woman who had been diagnosed with RH 20 years ago and had experienced recurrence four times during the past 20 years. This will increase the limited number of such cases in the hope of gaining a better understanding of this rare type of tumor.

View Article and Find Full Text PDF

An Acellular Platform to Drive Urinary Bladder Tissue Regeneration.

Adv Ther (Weinh)

January 2025

Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA; Division of Pediatric Urology, Department of Surgery, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA; Center for Regenerative Nanomedicine, Northwestern University, Chicago, IL 60611, USA; Department of Biomedical Engineering, McCormick School of Engineering, Northwestern University, Evanston, IL 60208, USA.

Impaired bladder compliance secondary to congenital or acquired bladder dysfunction can lead to irreversible kidney damage. This is managed with surgical augmentation utilizing intestinal tissue, which can cause stone formation, infections, and malignant transformation. Co-seeded bone marrow mesenchymal stem cell (MSC)/CD34+ hematopoietic stem cell (HSPC) scaffolds (PRS) have been successful in regenerating bladder tissue.

View Article and Find Full Text PDF

Myeloid malignancies are heterogenous disorders characterized by distinct molecular drivers but share convergence of oncogenic signaling pathways and propagation by ripe pro-inflammatory niches. Here, we establish a comprehensive transcriptional atlas across the spectrum of myeloproliferative neoplasms (MPN) and secondary acute myeloid leukemia (sAML) through RNA-sequencing of 158 primary samples encompassing CD34+ hematopoietic stem/progenitor cells and CD14+ monocytes. Supported by mass cytometry (CyTOF) profiling, we reveal aberrant networks of PI3K/AKT/mTOR signalling and NFκB-mediated hyper-inflammation.

View Article and Find Full Text PDF

Objective: Immune-related pancytopenia (IRP) is characterized by autoantibody-mediated destruction or suppression of bone marrow cells, leading to pancytopenia. This study aimed to explore the role of TRAPPC4 (trafficking protein particle complex subunit 4) as a key autoantigen in IRP, including epitope identification and immune activation mechanisms.

Methods: A total of 90 participants were included in the study, divided into four groups: 30 newly diagnosed IRP patients, 25 IRP remission patients, 20 patients with control hematologic conditions (severe aplastic anemia [SAA] and myelodysplastic syndrome [MDS]), and 15 healthy controls.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!